<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04172610</url>
  </required_header>
  <id_info>
    <org_study_id>K 2019-9546</org_study_id>
    <nct_id>NCT04172610</nct_id>
  </id_info>
  <brief_title>Prevalence of Influenza RelAted Invasive Aspergillosis</brief_title>
  <acronym>PIRAIA</acronym>
  <official_title>The Prevalence of Influenza Related Invasive Aspergillosis in Swedish Intensive Care Units</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter study with the aim to determine the prevalence of influenza-related
      invasive pulmonary aspergillosis in Swedish intensive care units and to assess the clinical
      impact of and risk factors for influenza-related invasive pulmonary aspergillosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter prospective observational study conducted at 12 intensive care units
      (ICU) in Sweden. All patients &gt;18 years of age with a Polymerase Chain Reaction
      (PCR)-verified influenza A or B diagnosed up to 7 days before admission to the ICU or during
      ICU care, will be included in the study.

      A new clinical routine has been implemented at the study centers: During the ICU stay
      screening with Beta-D-glucan and Galactomannan in blood/serum will be performed twice weekly
      and a respiratory sample will be retrieved for fungal culture and microscopy once weekly.

      All results from collected samples will be available to the patient's attending physicians.
      Clinical and microbiological data will be collected, and the diagnosis of invasive
      aspergillosis will be made using predefined diagnostic criteria.

      Objectives:

        1. To determine the prevalence of influenza-related invasive pulmonary aspergillosis in
           Swedish intensive care units

        2. To assess the clinical impact of and risk factors for influenza-related invasive
           pulmonary aspergillosis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of proven or probable invasive pulmonary aspergillosis</measure>
    <time_frame>From date of enrollment up to 90 days after enrollment</time_frame>
    <description>Enrolled patients will be categorized as proven or probable invasive pulmonary aspergillosis at discharge from the ICU.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure assessment Score (in patients diagnosed with proven/probable invasive pulmonary aspergillosis and those that were not)</measure>
    <time_frame>from date of admission to ICU to date of discharge from ICU, approximately 21 days</time_frame>
    <description>Registered once daily. Range 0-24, a higher score indicates a higher mortality risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of mechanical ventilation (in patients diagnosed with proven/probable invasive pulmonary aspergillosis and those that were not)</measure>
    <time_frame>from date of admission to ICU to date of discharge from ICU, approximately 21 days</time_frame>
    <description>Yes/No. Registered once daily.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of non-invasive ventilation (in patients diagnosed with proven/probable invasive pulmonary aspergillosis and those that were not)</measure>
    <time_frame>from date of admission to ICU to date of discharge from ICU, approximately 21 days</time_frame>
    <description>Yes/No. Registered once daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of vasopressor (in patients diagnosed with proven/probable invasive pulmonary aspergillosis and those that were not)pulmonary aspergillosis and those that were not)</measure>
    <time_frame>from date of admission to ICU to date of discharge from ICU, approximately 21 days</time_frame>
    <description>Yes/No. Registered once daily.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of renal replacement therapy (in patients diagnosed with proven/probable invasive pulmonary aspergillosis and those that were not)</measure>
    <time_frame>from date of admission to ICU to date of discharge from ICU, approximately 21 days</time_frame>
    <description>Yes/No. Registered once daily.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Respiratory Distress Syndrome (in patients diagnosed with proven/probable invasive pulmonary aspergillosis and those that were not)</measure>
    <time_frame>from date of admission to ICU to date of discharge from ICU, approximately 21 days</time_frame>
    <description>Registered once daily, using the Berlin-definition (mild 200 mm Hg &lt; PaO2/FIO2 ≤ 300 mm Hg), moderate (100 mm Hg &lt; PaO2/FIO2 ≤ 200 mm Hg), and severe (PaO2/FIO2 ≤ 100 mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of ICU stay (in patients diagnosed with proven/probable invasive pulmonary aspergillosis and those that were not)</measure>
    <time_frame>from date of admission to ICU to date of discharge from ICU, approximately 21 days</time_frame>
    <description>Median number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality (in patients diagnosed with proven/probable invasive pulmonary aspergillosis and those that were not)</measure>
    <time_frame>from date of admission to ICU to date of discharge from ICU, approximately 21 days</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality after ICU admission (in patients diagnosed with proven/probable invasive pulmonary aspergillosis and those that were not)</measure>
    <time_frame>from date of ICU admission to 90 days after ICU admission</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Invasive Pulmonary Aspergillosis</condition>
  <condition>Influenza, Human</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients ≥18 years of age with confirmed influenza A or B diagnosed up to 7 days before
        ICU admission, or during ICU care, will be included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed influenza A or B diagnosed up to 7 days before ICU admission, or during ICU
             care

          -  Admitted to the ICU

        Exclusion Criteria:

        - Under 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Krifors, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markus Castegren, M.D. Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ola Blennow, M.D. Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johan Petersson, M.D. A/Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anders Krifors, M.D.</last_name>
    <phone>+46707705044</phone>
    <email>anders.krifors@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Markus Castegren, M.D. Ph.D.</last_name>
    <phone>+46709723276</phone>
    <email>markus.castegren@sll.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICU at Mälarsjukhuset</name>
      <address>
        <city>Eskilstuna</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesper Sperber, M.D. Ph.D.</last_name>
      <email>jesper.sperber@dll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICU at Helsingborgs lasarett</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Stjärne Aspelund, M.D. Ph.D.</last_name>
      <email>anna.stjarne_aspelund@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICU at Länssjukhuset Ryhov</name>
      <address>
        <city>Jönköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Hammarskjöld, M.D. Ph.D.</last_name>
      <email>fredrik.hammarskjold@rjl.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICU at Universitetssjukhuset</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lina De Geer, M.D. Ph.D.</last_name>
      <email>lina.de.geer@regionostergotland.se</email>
    </contact>
    <contact_backup>
      <last_name>Anita Hällgren, M.D. Ph.D.</last_name>
      <email>anita.hallgren@liu.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ICU at Skånes universitetssjukhus</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Påhlman, M.D. Ph.D.</last_name>
      <email>lisa.pahlman@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICU at Skånes universitetssjukhus</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Hammarskjöld, M.D. Ph.D.</last_name>
      <email>johan.tham@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICU at Danderyds sjukhus</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrik Gille-Johnson, M.D. Ph.D.</last_name>
      <email>patrik.gille-johnson@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICU at Karolinska Universitetssjukhuset Huddinge</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Castegren, M.D. Ph.D.</last_name>
      <email>markus.castegren@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICU at Karolinska Universitetssjukhuset Solna</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Petersson, M.D. A/Prof.</last_name>
      <email>johan.petersson@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICU at Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Janols, M.D. Ph.D.</last_name>
      <email>helena.janols@akademiska.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICU at Västmanlands sjukhus</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Lemberg, M.D.</last_name>
      <email>marie.lemberg@regionvastmanland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICU at Universitetssjukhuset</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Källman, M.D. Ph.D.</last_name>
      <email>jan.kallman@regionorebrolan.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.piraiastudy.se</url>
    <description>Official Study Website</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Anders Krifors</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures and appendices)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04172610/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

